SCHEMBL30701246

SCHEMBL30701246

N#Cc1ccnc(C#N)c1C#N

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LRRK2 Q5S007 3/20 0.34
ROCK2 O75116 4/20 0.33
ROCK1 Q13464 4/20 0.33
CDC42BPA Q5VT25 4/20 0.33
CDC42BPB Q9Y5S2 4/20 0.33
ALDH1A1 P00352 7/20 0.33
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
CYP1A2 P05177 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
SMN1; SMN2 Q16637 2/20 0.32
HIF1A Q16665 1/20 0.32
GAA P10253 2/20 0.32
MAPT P10636 2/20 0.32
HPGD P15428 2/20 0.32
NPSR1 Q6W5P4 2/20 0.32
USP2 O75604 1/20 0.32
KDM4E B2RXH2 4/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1996285 1.00 LRRK2 (0.34) LRRK2ROCK2ROCK1CDC42BPACDC42BPB
SCHEMBL27176187 0.76 PRKACA (0.45) ALDH1A1MEN1KMT2ACYP1A2CYP2C9
SCHEMBL6060756 0.76 LRRK2 (0.33) LRRK2ROCK2ROCK1CDC42BPACDC42BPB
SCHEMBL15680079 0.76 ROCK2 (0.39) LRRK2ROCK2ROCK1CDC42BPACDC42BPB
SCHEMBL17570530 0.76 TSHR (0.37) LRRK2ROCK2ROCK1CDC42BPACDC42BPB
SCHEMBL21927522 0.76 LRRK2 (0.33) LRRK2ROCK2ROCK1CDC42BPACDC42BPB
SCHEMBL15691383 0.76 ALDH1A1 (0.39) LRRK2ALDH1A1MEN1KMT2ACYP1A2
SCHEMBL21927178 0.76 LRRK2 (0.33) LRRK2ROCK2ROCK1CDC42BPACDC42BPB
SCHEMBL8421629 0.73 ALDH1A1 (0.32) LRRK2ROCK2ROCK1ALDH1A1MEN1
SCHEMBL13082114 0.71 KDM4E (0.38) LRRK2ALDH1A1MEN1KMT2ACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250388468-A1 METHOD FOR PRODUCING SULFIDE SOLID ELECTROLYTE IDEMITSU KOSAN CO.,LTD. (JP) 2025-12-25 US disclosed
EP-4553860-A1 METHOD FOR PRODUCING SULFIDE SOLID ELECTROLYTE Idemitsu Kosan Co.,Ltd. (JP) 2025-05-14 EP disclosed
EP-4553862-A1 METHOD FOR PRODUCING SULFIDE SOLID ELECTROLYTE Idemitsu Kosan Co.,Ltd. (JP) 2025-05-14 EP disclosed
CN-119506380-A Fermentation control process method for improving synthesis of nicotinamide riboside 江西海文生物科技有限公司 2025-02-25 CN disclosed
WO-2023241349-A1 NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM BATTERY 张家港市国泰华荣化工新材料有限公司 2023-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250388468-A1 METHOD FOR PRODUCING SULFIDE SOLID ELECTROLYTE JAK1, JAK2, SLC6A12 LRRK2 110/4885ROCK2 1239/4885ROCK1 547/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.